

Under the auspices of



RISE MPN 2026

*Can we
engineer
disease
trajectories
in
MPNs?*

6 - 7 NOVEMBER
COURTYARD BY MARRIOTT
ROME CENTRAL PARK



risempn.org

RiseMPN 2026

Can we engineer disease trajectories in MPNs?

Scientific Programme

6–7 November 2026 | Courtyard by Marriott
Rome Central Park

Congress Presidents:

Alessandro Lucchesi · Gerardo Musuraca ·

Antonino Musolino

IRST “Dino Amadori” IRCCS, Meldola



DAY 1 — Friday, 6 November 2026

08:50–08:55 Welcome

Alessandro Lucchesi, Gerardo Musuraca and
Antonino Musolino

Congress Presidents

08:55–09:15 RISE LECTURE I [20 min]

Distinguished Chair: Sara Galimberti

Tiziano Barbui — Risk as a trajectory: from static
scores to dynamic disease engineering in MPNs

09:20–10:35 Session 1 — Blueprint: the
biological levers we can actually pull [75 min]

Chairs: Alessandro Lucchesi, Elena Masselli

Hans Hasselbalch — From clonal aging to early
interception: CHIP clinics as a model for MPN
prevention

Francisca Ferrer-Marín — Inflammasome Activation
and IL-1 Signalling in MPNs and MDS/MPN:
Inflammation as a Targetable Biological Lever

Nageswara Rao Tata — Metabolic Vulnerabilities
and Tractable Diagnostic and Therapeutic Targets of
the MPN Clone

Daniele Tibullo — Metabolic reprogramming in the
MPN niche: lactate, immune escape, and targetable
vulnerabilities

**Discussion: “Which lever first: clone, niche, vessel,
or host?”**

10:35–10:50 Coffee Break

10:50–12:05 Session 2 — MF: build the
platform, then add the modifier [75 min]

Chairs: Giuseppe Palumbo, Andrea Patriarca

Alessandro Lucchesi — Dynamic risk in myelofibrosis:
anaemia as trajectory sensor and the first readable
signal of disease modification

Daniele Cattaneo — First-line MF: navigating JAK
inhibitor selection and the evolving treatment algorithm

John Mascarenhas — MF combination landscape:
emerging combinations and where they fit the platform

Florian Heidel — MDM2/p53 and clone-stress
strategies: from biology to combination rationale in MF

**Discussion: “What is the clearest ‘disease-mod’
signal today?”**

12:05–12:20 BRIDGE LECTURE I [15 min]

Distinguished Chair: Mariasanta Napolitano

Haifa Kathrin Al-Ali — Thrombotic recurrence in MPNs:
the unmet need that proves disease modification is
not yet complete

12:20–12:50 STRATEGIC DIALOGUE — Engineering
the MF trajectory: a transatlantic perspective

[30 min]

Moderator: Danijela Leković

Jennifer O’Sullivan — European perspective:
translational biology, real-world evidence, and how
they reshape MF decisions (10 min)

Tania Jain — US perspective: molecular risk architecture, transplant positioning, and the MDS/MPN boundary as a trajectory signal (10 min)
Moderated exchange: 10 min.

12:50-14:05 Session 3 — The rational add-on toolbox: epigenetic, signalling, and erythroid targets [75 min]

Chairs: **Jennifer O'Sullivan, Florian Heidel**

Andrea Patriarca — BET/HDAC/LSD1 inhibitors in MF: what epigenetic modifiers really change

Michael Loschi — Non-JAK resistance nodes as combo targets: PI3K δ , PIM, and CDK8-19 inhibitors in the synergy playbook

Domenico Girelli — Iron metabolism as a biological lever: hepcidin, erythroferrone, and the logic of pathway interference

Giuseppe Palumbo — Activin ligand traps and TGF- β pathway modulators for MF anaemia: clinical evidence and positioning

Discussion: “Mechanism → positioning: how to avoid ‘combo tourism’.”

14:05-15:00 Lunch + Industry Lunch Symposium
Sponsor GSK

INDUSTRY LUNCH SYMPOSIUM

Shaping the Treatment Trajectory for Patients with Myelofibrosis and Anemia

Moderator: **A. Lucchesi**

First-Line Treatment Choices in Myelofibrosis: Setting the Trajectory from the Start – **Prof. E. Rossi**

Real-World Evidence, Switch Criteria and the Case for Early Switch in Myelofibrosis and Anemia – **Prof. G. Palumbo**

15:00-16:15 Session 4 — PV and ET: upstream trajectory change (before it becomes irreversible) [75 min]

Chairs: **Danijela Leković, Srinivas Tantravahi**

Erika Morsia — ET beyond cytoreduction: where epigenetic modifier strategies belong

Elena Rossi — Deceptive calm: acquired coagulopathy in ET, from occult bleeding risk to unpredictable thrombotic phenotypes

Heinz Gisslinger — Masked polycythaemia vera and long-term interferon response: recognising the hidden trajectory and modifying it (20 min)

Marina Kremyanskaya — Iron-axis therapeutics in PV: hepcidin mimetics and TMPRSS6-silencing agents — clinical data and positioning

Discussion: “Can PV/ET be engineered like CML was?”

16:15-17:15 Session 5 — Vessel-first reality check: thrombosis, cardiovascular burden, and pragmatic prevention [60 min — 3 talks]

Chairs: **Hans Hasselbalch, Guglielmo Mariani**

Mariasanta Napolitano — Thrombotic emergencies in MPNs: acute management, atypical sites, and what changes practice

Giulio Giordano — Platelets, niche and advanced MF phenotypes: why thrombocytopenia is a biology signal

Olga Demska — Atrial fibrillation in MPNs: an underrecognised complication reshaping vascular management

Discussion: “What do we treat first when the ‘vessel’ is screaming?”

17:15-17:35 THE RISE RITUAL — Evening Reflections and Networking Pause

“A Sip of Insight” — a symbolic glass of wine, paired with an artisan chocolate. Each attendee receives a “Rise Note” card with the 2026 quote of the year and space to capture a thought, question, or inspiration.





17:35–18:40 Session 6 — Preclinical Spotlight: why the next trials should work [65 min]

Distinguished Chairs:

Sara Galimberti, Thomas Fischer

Invited Talk (15 min):

Elena Masselli — Beyond the biopsy: can CCR2⁺CD34⁺ cell dynamics and functional imaging stage fibrosis non-invasively?

Tutor + Emerging Talent — Pair 1 (10 + 10 min):

Sara Galimberti — Contextualising splenic micro-environment research: from biology to transplant implications (Distinguished Chair / Tutor)

Edoardo Peroni — Spatially Resolved Transcriptomics Profiling Reveals Compartmentalised Inflammatory and Fibrogenic Circuits in the Myelofibrosis Spleen (Best Abstract Winner #1, RiseMPN 2025)

Tutor + Emerging Talent — Pair 2 (10 + 10 min):

Thomas Fischer — Contextualising oxidative stress and signalling in MPN neutrophils: the pathway landscape (Distinguished Chair / Tutor)

Enrico La Spina — Uncoupled NRF2 Activation and Persistent Unfolded Protein Response Characterise Neutrophils in Myelofibrosis (Best Abstract Winner #2, RiseMPN 2025)

Discussion: “From bench to trial: what these findings change for combination design.”

18:40–18:50 Closing Day 1

Key take-aways and “questions to answer tomorrow.”

DAY 2 — Saturday, 7 November 2026

08:30–08:45 Welcome Back

08:45–09:55 Session 7 — Patients that force the strategy to be real [70 min — 4 talks]

Chairs: **Federica Frabetti, Marina Kremyanskaya**

Novella Pugliese — Recurrent miscarriage in MPNs: decisions, trade-offs, trajectories

Marta Sobas — AYA-MPN: lifelong trajectory engineering starts here

Giorgia Micucci — Bleeding syndromes in MPN: the ‘other side’ of vascular medicine

Giovanni Caocci — Quality of life in polycythaemia vera: iron bioavailability, the phlebotomy burden, and the perception gap between physicians and patients

Discussion: “Personalised strategy is not a slogan: what changes Monday morning?”

10:10–10:30 BRIDGE LECTURE II [20 min]

Distinguished Chair: **Claudio Cerchione**

Daniela Cilloni — Nuclear trafficking and the biology of XPO1

10:10 Open Coffee

10:25–11:40 Session 8 — Precision diagnostics to steer combos (and prove modification) [75 min]

Chairs: **Francesco Malaspina, Elena Rossi**

Ciro Rinaldi — CALR and CD47 dynamics: immunologic targets and anti-CALR logic

Paola Guglielmelli — NGS architecture and response-adaptive monitoring: making trials ‘trajectory-aware’

Nicola Gentili — Federated learning at the service of clinical scores: real-world evidence infrastructure for MPN

trajectory monitoring

Andrea Duminuco — Interpretable scores and composite vascular risk to guide strategy

Discussion: “If you can’t measure it, you can’t engineer it.”

11:40–12:55 Session 9 — When the trajectory accelerates: transplant, blast phase, and the limits of modification [75 min]

Chairs: **Gerardo Musuraca, John Mascarenhas**

Selene Guerzoni — Bridge-to-transplant in MF: how modern therapy changes candidacy and timing

Francesco Saraceni — Allo-SCT in older MF: realistic pathways and decision thresholds

Patrizia Chiusolo — Predicting post-SCT outcomes: how ‘modification’ shows up after the cure attempt

Jose Torregrosa — Accelerated and blast phase MPN: recognising the turning point and rewriting the endgame

Expert Discussant: Tania Jain (Johns Hopkins) — structured commentary on transplant timing and molecular risk integration

Discussion: “When is ‘enough improvement’ enough to move?”

12:55–14:25 Session 10 — Beyond classical MPN: lessons from CML, mastocytosis, HES [90 min — 5 talks]

Chairs: **Elisabetta Abruzzese, Gianantonio Rosti**

Mario Tiribelli — CML: positioning third-generation TKIs and allosteric BCR-ABL1 inhibitors in 2026 practice

Srinivas Tantravahi — New clinical trials in CML: what they teach us about deep targets and MRD

Carmen Fava — CML monitoring in 2026: methodologies, treatment-free remission, and the challenge of atypical transcripts

Daniela Cilloni — Systemic mastocytosis: targeted therapies and real endpoints in advanced disease

Giuseppe Gaetano Loscocco — HES: targeted approaches and trajectory control in eosinophil-driven disease

Discussion: “What can MPN steal (ethically) from these playbooks?”

14:30–15:10 Buffet + Poster Walk + Best Poster Award + Industry Symposium 2 [45 min]

Posters displayed in the networking/lunch area.

Poster Walk co-led by Monica Poggiaspalla and Giovanni Martinelli on behalf of the Scientific Committee.

Industry Symposium 2 runs as a parallel option.

Sponsor tbd.

Best Poster Award (~14:45) — Presented by the RiseMPN Scientific Committee. The award includes full hospitality for RiseMPN 2027.

15:10–15:20 Closing Remarks [10 min]

Moderators: **Alessandro Lucchesi, Gerardo Musuraca, Antonino Musolino**

Key messages, acknowledgements, and preview of RiseMPN 2027.

The RiseMPN Trajectory Statement 2026 will be developed as a post-congress publication.



FACULTY

Congress Presidents

Alessandro Lucchesi

IRST “Dino Amadori” IRCCS, Meldola, Italy

Gerardo Musuraca

IRST “Dino Amadori” IRCCS, Meldola, Italy

Antonino Musolino

IRST “Dino Amadori” IRCCS, Meldola, Italy

Rise Lectures

Tiziano Barbui — FROM — Fondazione per la Ricerca

Ospedale di Bergamo, Italy

Giovanni Martinelli — IRCCS Azienda Ospedaliero-

Universitaria di Bologna, Istituto di Ematologia

“Seràgnoli”, Italy

Distinguished Chairs

Sara Galimberti — University of Pisa, Italy

Thomas Fischer — Otto-von-Guericke University,

Magdeburg, Germany

Mariasanta Napolitano — University of Palermo, Italy

Strategic Dialogue

Danijela Leković — University Clinical Center

of Serbia, Belgrade, Serbia

Jennifer O’Sullivan — MRC Weatherall Institute

of Molecular Medicine, University of Oxford, UK

Tania Jain — Johns Hopkins University, Baltimore, USA

Session Speakers (alphabetical)

Haifa Kathrin Al-Ali — Universitätsklinikum Halle

(Saale), Germany

Giovanni Caocci — University of Cagliari / AOU

Cagliari, Italy

Daniele Cattaneo — Fondazione IRCCS Ca’ Granda

Ospedale Maggiore Policlinico, Milan, Italy

Patrizia Chiusolo — Fondazione Policlinico Universi-

tario A. Gemelli IRCCS, Rome, Italy

Daniela Cilloni — University of Turin, Italy

Olga Demska — Wrocław Medical University,

Wrocław, Poland

Andrea Duminuco — AOU Policlinico “G. Rodolico”,

Catania, Italy

Carmen Fava — University of Turin, Italy

Francisca Ferrer-Marín — IIS-Fundación Jiménez

Díaz, UCAM, Madrid, Spain

Nicola Gentili — IRST “Dino Amadori” IRCCS, Mel-

dola, Italy

Heinz Gisslinger — Medical University of Vienna,

Austria

Giulio Giordano — A.O.R.N. “A. Cardarelli”,

Campobasso, Italy

Domenico Girelli — University of Verona, Italy

Paola Guglielmelli — CRIMM, University of Florence

/ AOU Careggi, Italy

Selene Guerzoni — IRST “Dino Amadori” IRCCS,

Meldola, Italy

Hans Hasselbalch — Zealand University Hospital,

Roskilde, Denmark

Florian Heidel — Medizinische Hochschule Hannover

(MHH), Germany

Marina Kremyanskaya — Icahn School of Medicine

at Mount Sinai, New York, USA

Enrico La Spina — University of Catania, Italy

Giuseppe Gaetano Loscocco — CRIMM, University of

Florence / AOU Careggi, Italy

Michael Loschi — CHU de Nice, France

Alessandro Lucchesi — IRST “Dino Amadori” IRCCS,

Meldola, Italy

John Mascarenhas — Icahn School of Medicine at

Mount Sinai, New York, USA

Elena Masselli — University of Parma, Italy

Giorgia Micucci — IRST “Dino Amadori” IRCCS,

Meldola, Italy
Erika Morsia — Università Politecnica delle Marche, Ancona, Italy
Mariasanta Napolitano — University of Palermo, Italy
Giuseppe Palumbo — University of Catania, Italy
Andrea Patriarca — University of Eastern Piedmont, Novara, Italy
Edoardo Peroni — Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
Novella Pugliese — Federico II University, Naples, Italy
Ciro Rinaldi — University of Lincoln, UK
Elena Rossi — Fondazione Policlinico Universitario A. Gemelli IRCCS / Università Cattolica, Rome, Italy
Francesco Saraceni — Università Politecnica delle Marche, Ancona, Italy
Marta Sobas — Wrocław Medical University, Wrocław, Poland
Srinivas Tantravahi — University of Utah / Huntsman Cancer Institute, Salt Lake City, USA
Nageswara Rao Tata — Cantonal Hospital St. Gallen, Switzerland
Daniele Tibullo — University of Catania, Italy
Mario Tiribelli — University of Udine, Italy
Jose Torregrosa — CHU de Poitiers, France

Chairs & Moderators

Elisabetta Abruzzese — Ospedale Sant'Eugenio, Rome, Italy
Claudio Cerchione — IRST "Dino Amadori" IRCCS, Meldola, Italy
Daniela Cilloni — University of Turin, Italy
Thomas Fischer — Otto-von-Guericke University, Magdeburg, Germany
Federica Frabetti — IRST "Dino Amadori" IRCCS, Meldola, Italy
Sara Galimberti — University of Pisa, Italy
Hans Hasselbalch — Zealand University Hospital,

Roskilde, Denmark
Marina Kremyanskaya — Icahn School of Medicine at Mount Sinai, New York, USA
Alessandro Lucchesi — IRST "Dino Amadori" IRCCS, Meldola, Italy
Francesco Malaspina — IRST "Dino Amadori" IRCCS, Meldola, Italy
Guglielmo Mariani — Department of Science and Technology, University of Westminster, London, UK
John Mascarenhas — Icahn School of Medicine at Mount Sinai, New York, USA
Elena Masselli — University of Parma, Italy
Gerardo Musuraca — IRST "Dino Amadori" IRCCS, Meldola, Italy
Jennifer O'Sullivan — MRC WIMM, University of Oxford, UK
Giuseppe Palumbo — University of Catania, Italy
Andrea Patriarca — University of Eastern Piedmont, Novara, Italy
Monica Poggiaspalla — IRST "Dino Amadori" IRCCS, Meldola, Italy
Elena Rossi — Fondazione Policlinico Universitario A. Gemelli IRCCS / Università Cattolica, Rome, Italy
Gianantonio Rosti — IRST "Dino Amadori" IRCCS, Meldola, Italy
Srinivas Tantravahi — University of Utah / Huntsman Cancer Institute, USA

Expert Discussant

Tania Jain — Johns Hopkins University, Baltimore, USA

Poster Walk

Monica Poggiaspalla — IRST "Dino Amadori" IRCCS, Meldola, Italy
Giovanni Martinelli — IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy

1. Scientific Rationale

Over the past decade, myeloproliferative neoplasms have moved from being viewed as indolent chronic disorders to paradigmatic models of clonal haematopoiesis, vascular injury and systemic inflammation. RiseMPN 2025 explored this landscape by focusing on inflamed vessels and clonal survival: how fire in the blood and niche remodelling shape thrombosis, fibrosis and disease progression. That meeting asked why disease trajectories diverge.

RiseMPN 2026 asks a bolder question: can we engineer disease trajectories in MPNs?

The therapeutic toolkit is expanding rapidly. JAK inhibition has transformed symptom control and splenomegaly, but has only partially delivered on the promise of disease modification. At the same time, a new generation of agents is emerging: interferons and other immunomodulators, anti-inflammatory and anti-fibrotic approaches, hepcidin and activin ligand targeting drugs, epigenetic and transcriptional modulators, p53/MDM2 and BCL2 family inhibitors, rational antithrombotic and cardiometabolic strategies. The central challenge for the next decade is no longer merely what works, but which combinations, in which patients, at which time point, can genuinely rewrite the natural history of disease.

RiseMPN 2026 is designed as a translational dialogue across three axes: Mechanism, Combination, Trajectory.

First, we map the pathway constellations that matter most for synergy, from JAK/STAT and inflammatory signalling to metabolic stress, niche reprogramming and immune escape. Second, we critically appraise emerging combination strategies in myelofibrosis, polycythaemia vera and essential thrombocythae-

mia, moving beyond single agent narratives to consider how layering therapies can achieve fibrosis regression, molecular clearance, vascular protection and durable haematologic remissions. Third, we confront the strategic questions that increasingly shape daily practice: early versus delayed intensification, add on versus switch, integration with allogeneic transplantation, and the role of real world data and AI driven models in guiding these choices.

Central to this discussion is the need to define what we mean by disease modification in MPNs. Across the programme we revisit our endpoints: from spleen volume and symptom scores to dynamic measures of allele burden, bone marrow architecture, clonal competition, cardiovascular risk and quality of life. We examine how to design disease modifying trials, how to read intermediate signals along a trajectory, and how to balance efficacy, safety, cost and feasibility in a field where many patients will never see a transplant but all deserve a rational long term plan.

RiseMPN 2026 therefore aims to be more than an update meeting. It is an invitation to the MPN community to think and act as trajectory engineers: to integrate mechanism with clinical reality, combination design with strategic positioning, and innovative endpoints with meaningful benefit for patients.

2. Venue and General Information

Venue

Courtyard by Marriott Rome Central Park

Via Giuseppe Moscati 7, 00168 Rome, Italy

Getting there

The venue is located in the Gemelli and Monte Mario area, in the northwest of Rome. Fiumicino Airport is approximately 35 minutes away by car.

From Fiumicino – Leonardo da Vinci International Airport: approximately 39 km from the hotel.

From Ciampino – G.B. Pastine International Airport: approximately 35 km from the hotel.

From Roma Termini railway station: take Metro Line A to Valle Aurelia, then the regional train to Gemelli station.

Public transport: the nearest railway station is Gemelli (FM3 line). The nearest Metro station is Battistini (Line A).

Airport shuttle: the hotel does not provide an airport shuttle service. Private car service can be arranged on request.

Official language

Official language: English

Simultaneous translation: Not provided.

Climate

In early November, Rome generally enjoys mild autumn weather, with daytime temperatures around 16–18°C and nighttime temperatures around 8–10°C. Rain is possible, so a light waterproof jacket or umbrella is recommended

Registration

Participation is free of charge. Registration is compulsory.

Participants are required to register on the Xenia educational platform at didattica.xeniaeventi.it and enrol in the RiseMPN 2026 course.

3. Italian CME Credits (ECM)

The event has been accredited within the Italian Continuing Medical Education (ECM) programme.

Provider: Xenia S.a.s. di Mazza Francesca & C. – Standard ECM Provider ID 5090

Event number: 493199

ECM ID: 5090-493199

Credits: 14 CME credits

Training hours: 14

Training objective: Guidelines – Protocols – Procedures

PROFESSION AND DISCIPLINES

Profession: Physician

Disciplines: Haematology; Medical Genetics; Oncology; Pathological Anatomy; Clinical Biochemistry; Clinical Pharmacology and Toxicology; Transfusion Medicine; Clinical Pathology (Clinical Chemistry and Microbiology Laboratory); General Practice (Family Physicians).

CME LEARNING ASSESSMENT

The **online learning questionnaire** (double randomisation and no possibility of retaking) will be available from **8:00 p.m. on 7 November 2026**.

The deadline for completing the questionnaire is **11:59 p.m. on 10 November 2026**.

Participants are also required to complete the **anonymous evaluation form**.

The **CME certificate** can be downloaded from the participant's personal area.

CME credits will be awarded subject to:

- attendance for at least **90% of the training hours**;
- completion of the online learning questionnaire with at least **75% correct answers**;
- completion of the anonymous evaluation form.

4. Call for Abstracts

Abstract submission is open to clinicians, researchers and healthcare professionals working on myeloproliferative neoplasms and related myeloid disorders.

Scope: Polycythaemia vera, essential thrombocythaemia, myelofibrosis, chronic myeloid leukaemia, systemic mastocytosis, hypereosinophilic syndromes. Basic, translational or clinical work

Length: 400 words maximum

Submission: By email to info@xeniaeventi.it

Deadline: 20 October 2026

Notification of acceptance: 31 October 2026

Presentation: Accepted abstracts are presented during the Poster Walk on Saturday 7 November

Best Poster Award

All accepted posters are eligible for the Best Poster Award. The award includes full hospitality at RiseMPN 2027, and the winner is invited to present the work in the Preclinical Spotlight session of the following edition.

Guidelines and evaluation criteria are available at rise-mpn.org

5. Sponsors and Auspices

Supported by an unrestricted educational grant from

Gold Sponsor



Silver Sponsor



Supporting Sponsor




Under the auspices of

- SIAM, Società Italiana di Intelligenza Artificiale in Medicina
- Accord
- Amgen
- Astellas
- Bayer-Orion
- Bms
- Daiichi Sankyo-Astra
- Eisai
- Ely Lilly
- Gilead
- Janssen
- Merck Serono
- Msd
- Pfizer
- Pharmamar
- Pierre Fabre Pharma
- Regeneron
- Roche
- Servier
- Sophos
- Sos Medicali
- Takeda
- Menarini
- Beone
- Dymalife

Can we engineer
disease trajectories
in MPNs?



risempn.org



RISE
MPN
2026

risempn.org